Intracellular trapping of therapeutics or tracer agents

Claim 3

A method according to claim 1 wherein said therapeutic or tracer agent is bound to said cellobiose by reductive amination.

Claim 4

A method according to claim 2 wherein said agent is tyramine.

Claim 5

A method according to claim 2 wherein said agent is a primary amine chelating agent capable of carrying radio-metals.

Claim 6

A method according to claim 4 wherein said chelating agent is p-aminophenyl-ethylenedinitrilotetraacetic acid.

Claim 7

A method according to claim 3 wherein said tyramine is labeled with a radioisotope.

Claim 8

A method according to claim 2 wherein said agent is a compound enriched in 10 B and containing a primary amino group.

Claim 9

A method according to claim 7 wherein said agent is 2-(p-aminophenyl)-1,2-dicarba-closo-dodecaborane which is enriched in 10 B.

Claim 10

A method according to claim 1 wherein said targeting agent is selected from the group consisting of peptides, proteins antibiotics or glycoproteins.

Claim 11

A method according to claim 9 wherein said targeting agent is selected from the group consisting of antibodies, fragments or derivative products of antibodies, hormones and hormone analogues.

Claim 12

An intracellularly trappable adduct adapted to provide trapping of a therapeutic or tracer agent within cells comprising cellobiose having said agent bound thereto by a nonmetabolizable bond.

Claim 13

An intracellularly trappable adduct adapted to provide trapping of a therapeutic or tracer agent within cells comprising cellobiose having said agent bound thereto by a nonmetabolizable bond.

Claim 14

An adduct according to claim 11 wherein said agent includes a primary amine that is bound to cellobiose by reductive amination.

Claim 15

An adduct according to claim 12 wherein said agent is tyramine.

Claim 16

An adduct according to claim 12 wherein said agent is labeled with a radioisotope.

Claim 17

An adduct according to claim 12 wherein said agent is a chelating agent capable of carrying radio-metals.

Claim 18

An adduct according to claim 15 wherein said chelating agent is p-aminophenyl-ethylenedinitrilotitraacetic acid.

Claim 19

An adduct according to claim 11 wherein said agent is a compound rich in 10 B and containing a primary amino group.

Claim 20

An adduct according to claim 17 wherein said agent is 2-(p-aminophenyl)-1,2-dicarba-closo-dodecaborane.

Claim 21

A targeted adduct comprising the adduct according to claim 11 bound to a targeting agent.

Claim 22

A targeted adduct according to claim 19 wherein said targeting agent is a peptide, protein, glycoprotein or antibiotic.

Claim 23

A targeted adduct according to claim 20 wherein said targeting agent is an antibody fragment or derivative product of an antibody, hormone or hormone analog.

Claim 24

A targeted adduct according to claim 20 wherein said targeting agent is a protein chemically derivatized so as to cause it to be targeted.

Claim 25

A targeted adduct according to claim 22 wherein said targeting agent is selected from the group consisting of asialoglycoproteins, lactosylated proteins, acetylated and acetoacetylated proteins or maleylated proteins.

Claim 26

A targeted adduct according to claim 23 wherein said targeting agent is selected from the group consisting of asialofetuin, asialotransferrin, lactosylated low density lipoprotein, acetylated or acetoacetylated low density lipoprotein or maleyated albumin.

Claim 27

A targeted adduct according to claim 20 wherein said adduct includes radiolabeled tyramine.

Claim 28

A method for determining protein metabolism within cells comprising the steps of: introducing into the cells a targeted adduct according to claim 19, said targeted adduct including a protein metabolizable within said cells conjugated to said adduct as said targeting agent, said targeted adduct being labeled with a first radioisotope, simultaneously introducing into the cells said metabolizable protein labeled with a second radioisotope, said second radioisotope being removed from said cells naturally when the protein to which they are bound is metabolized, wherein the amount of second radioisotope remaining in tissues containing said cells is a measure of unmetabolized protein in said tissues; subtracting the amount of second radioisotope in said tissues from the amount of first radioisotope within said tissues to thereby determine the metabolism of said protein within said cells.

Claim 29

A method for radiological imaging of target cells comprising the steps of: exposing tissues to a targeted adduct according to claim 19 wherein said adduct is labeled with a first radioisotope and includes a targeted protein metabolizable within target cells of said tissues, said first radioisotope being trapped within said cells along with said adduct to thereby provide a measure of total protein introduced into said cells as well as protein in said tissue but not within cells, said method including; simultaneously exposing said tissues to said targeted protein labeled with a second radioisotope, said second radioisotope not being trapped in said cells, to thereby provide a measure of non-degraded protein within said tissues; and subtracting the measure of non-degraded protein provided by said second radioisotope from the measure of total protein provided by said first radioisotope to enhance the radiological imaging of said target cells.